Abstract
Cancer, once considered as an incurable disease, today, becomes not that difficult to be treated due to the newly emerging nanotechnology and the rapid development of “smart” drug delivery systems. New cancer therapeutics ought to overcome the defects of conventional drug delivery systems, such as nonspecific bio-distribution or targeting, short circulation time, etc. Tumor targeted drug delivery systems basically includes two strategies: passive and active targeting. Passive targeting is often referred to the enhanced permeability and retention effect (EPR effect) due to the enhanced vascular penetration of tumor capillaries and limited lymphatic drainage of lymphatic capillaries. Active targeting systems are based on local stimuli characteristic of the target pathological zone (such as, increased temperature or lowered pH values, redox potential changes, characteristic of inflamed, the receptor mediated internalization by target cells, etc.). Intriguingly, the combination of the two strategies above is promising and exciting. Herein, we give a brief review of tumor targeted drug delivery systems based on tumor cell itself and its external milieu.
Keywords: Drug delivery systems, smart nanocarriers, tumor targeting, Carcinoma, conventional therapeutics, blood circulation, ENDOCYTOSIS, NANOMEDICINES, PASSIVE TARGETING
Drug Delivery Letters
Title: “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Volume: 1 Issue: 1
Author(s): Zhigang Hu, Fei Huo, Yi Zhang, Chunyang Chen, Kehua Tu, Hongliang Jiang and Li-Qun Wang
Affiliation:
Keywords: Drug delivery systems, smart nanocarriers, tumor targeting, Carcinoma, conventional therapeutics, blood circulation, ENDOCYTOSIS, NANOMEDICINES, PASSIVE TARGETING
Abstract: Cancer, once considered as an incurable disease, today, becomes not that difficult to be treated due to the newly emerging nanotechnology and the rapid development of “smart” drug delivery systems. New cancer therapeutics ought to overcome the defects of conventional drug delivery systems, such as nonspecific bio-distribution or targeting, short circulation time, etc. Tumor targeted drug delivery systems basically includes two strategies: passive and active targeting. Passive targeting is often referred to the enhanced permeability and retention effect (EPR effect) due to the enhanced vascular penetration of tumor capillaries and limited lymphatic drainage of lymphatic capillaries. Active targeting systems are based on local stimuli characteristic of the target pathological zone (such as, increased temperature or lowered pH values, redox potential changes, characteristic of inflamed, the receptor mediated internalization by target cells, etc.). Intriguingly, the combination of the two strategies above is promising and exciting. Herein, we give a brief review of tumor targeted drug delivery systems based on tumor cell itself and its external milieu.
Export Options
About this article
Cite this article as:
Hu Zhigang, Huo Fei, Zhang Yi, Chen Chunyang, Tu Kehua, Jiang Hongliang and Wang Li-Qun, “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems, Drug Delivery Letters 2011; 1 (1) . https://dx.doi.org/10.2174/2210304x11101010067
DOI https://dx.doi.org/10.2174/2210304x11101010067 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Posttranslational Modifications as Versatile Regulators of Parkin Function
Current Medicinal Chemistry Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure
CNS & Neurological Disorders - Drug Targets Multidrug Transporters as Drug Targets
Current Drug Targets Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Structure and Mechanism of Action of Tau Aggregation Inhibitors
Current Alzheimer Research Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets